Benefits of switching from typical to atypical antipsychotic medications: A longitudinal study in a community-based setting

被引:28
作者
Cook, PE
Goldberg, JO
Van Lieshout, RJ
机构
[1] Hamilton Program Schizophrenia, Hamilton, ON L8N 3Y3, Canada
[2] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON L8S 4L8, Canada
[3] Univ Ottawa, Ottawa, ON K1N 6N5, Canada
来源
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE | 2002年 / 47卷 / 09期
关键词
schizophrenia; atypical antipsychotic medication; longitudinal; community; resource utilization;
D O I
10.1177/070674370204700909
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: This study examines the clinical and resource utilization effects of switching stable outpatients with schizophrenia from a typical to an atypical antipsychotic medication. Method: We monitored 43 schizophrenia patients from a community mental health program who tolerated switching from typical to atypical antipsychotic medications. We used the Positive and Negative Syndrome Scale (PANSS), Lehman Quality of Life Interview (QOL), and service utilization data for 2 years before and 2 years after the switch. Results: The switch to atypical antipsychotics was associated with significant improvements in positive symptoms, in general psychopathology, and in quality of life. Resource requirements, including case-management and crisis services and hospitalization days, were significantly reduced. We observed no changes in the sample's already low levels of negative symptoms. Conclusions: In stable outpatients with schizophrenia in a real-world setting, switching to an atypical antipsychotic can result in sustained, significant improvement in clinical response and quality of life, as well as in reduced need for hospitalization and community support,.
引用
收藏
页码:870 / 874
页数:5
相关论文
共 18 条
[1]  
Bassett A, 1998, CAN J PSYCHIAT, V43, p25S
[2]   A comparative review of new antipsychotics [J].
Blin, O .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1999, 44 (03) :235-244
[3]   The use of atypical antipsychotics in the management of schizophrenia [J].
Campbell, M ;
Young, PI ;
Bateman, DN ;
Smith, JM ;
Thomas, SHL .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (01) :13-22
[4]  
CHOUINARD G, 1993, J CLIN PSYCHOPHARM, V13, P25
[5]   Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia? [J].
DeQuardo, JR ;
Tandon, R .
JOURNAL OF PSYCHIATRIC RESEARCH, 1998, 32 (3-4) :229-242
[6]  
Feltus M S, 1999, Can J Clin Pharmacol, V6, P187
[7]  
KANE JM, 1985, PSYCHOPHARMACOL BULL, V21, P23
[8]  
Kay S.R., 1991, POSITIVE NEGATIVE SY
[9]   THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) FOR SCHIZOPHRENIA [J].
KAY, SR ;
FISZBEIN, A ;
OPLER, LA .
SCHIZOPHRENIA BULLETIN, 1987, 13 (02) :261-276
[10]   A QUALITY OF LIFE INTERVIEW FOR THE CHRONICALLY MENTALLY-ILL [J].
LEHMAN, AF .
EVALUATION AND PROGRAM PLANNING, 1988, 11 (01) :51-62